+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
MALE
ID07538843

Real-world Study Evaluating Darolutamide Plus ADT Effectiveness and Safety in Men with Non-metastatic Castration-resistant Prostate Cancer After Prior Bicalutamide Treatment

Led by Bayer · Updated on 2026-08-18

800

Participants Needed

1

Research Sites

12 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are observing the effects of darolutamide combined with androgen deprivation therapy ADT in men with non-metastatic castration-resistant prostate cancer nmCRPC in China. These men previously received bicalutamide plus ADT for non-metastatic hormone-sensitive prostate cancer nmHSPC but their cancer progressed despite treatment. Prostate cancer is common and often diagnosed late in China, making new treatments important. Darolutamide has shown promise in controlling cancer progression with fewer severe side effects compared to older therapies. Participants in this observational study receive darolutamide and ADT according to local standard care practices. The study includes a main group of 800 men followed for 6 months and a smaller group of 100 men observed for 12 months. The study does not assign treatments but observes men treated with darolutamide and ADT after progression from prior therapy. Researchers will track prostate-specific antigen PSA levels and other health measures during this time. During the study, participants will have regular assessments to measure PSA levels, which help indicate cancer activity, and to monitor for any adverse medical events. The main outcome is how many men achieve undetectable PSA levels within 6 months, while the smaller group will be observed for PSA progression-free survival at 12 months. Safety is also monitored by recording any side effects or medical problems that occur. The total participation lasts up to 12 months depending on the group.

CONDITIONS

Brief Title

An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT Treatment

Research Team

B

Bayer Clinical Trials Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here